Small Molecules Derived from Plants and Fungi

Empyrean Neuroscience is pioneering a novel approach to treating severe neuropsychiatric and neurological diseases through the genetic engineering of small molecule therapeutics derived from fungi and plants. Their unique platform allows for the precise modification of neuroactive compounds by utilizing advanced genetic and bioinformatics techniques. This includes the ability to up-regulate and down-regulate specific genes, as well as perform genetic knock-outs and knock-ins, which enables the creation of tailored therapeutics aimed at addressing conditions such as depression, post-traumatic stress disorder, substance abuse disorders, and chronic pain.

The company has developed a rapid transformation and regeneration method for fungi and plants, facilitating the efficient development of a diverse pipeline of targeted compounds for human therapeutic use. Additionally, Empyrean has established a scalable Good Manufacturing Practice (GMP) process that supports the expansion of their technology across various species and therapeutic areas. This innovative approach not only addresses significant gaps in current treatment options but also holds the transformative potential to discover and develop novel small molecule therapeutics for a range of debilitating conditions.

United States

Empyrean is harnessing the power of genetic engineering to transform how we treat severe neuropsychiatric and neurologic diseases.

Empyrean Neuroscience

Company Details